Zobrazeno 1 - 10
of 797
pro vyhledávání: '"Clostridium difficile infections"'
Autor:
Aneta Głaz, Kinga Knop, Anna Kochanowska, Damian Wach, Zuzanna Piasecka, Ewelina Wesołek, Beata Kasztelan-Szczerbińska, Barbara Skrzydło-Radomańska
Publikováno v:
Journal of Education, Health and Sport, Vol 48, Iss 1 (2023)
Background: Proton pump inhibitors (PPIs) are widely used drugs that reduce gastric acid secretion. In recent years, there has been a gradual increase in their use. The safety of prolonged PPI therapy and the potential for cumulative side effects of
Externí odkaz:
https://doaj.org/article/e793f3b0bf3c48648c87b8aa29110a1c
Autor:
Hassan Mahmoudi, Hadi Hossainpour
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 29, Iss 1, Pp 3-11 (2023)
Fecal microbiota transplantation (FMT) restores a balanced intestinal flora, which helps to cure recurrent Clostridium difficile infections (RCDI). FMT has also been used to treat other gastrointestinal diseases, including inflammatory bowel disease
Externí odkaz:
https://doaj.org/article/af2e43f43be9412492416936413d19b1
Autor:
Watson, Troy, Hickok, Jason, Fraker, Sarah, Korwek, Kimberly, Poland, Russell E., Septimus, Edward
Publikováno v:
Clinical Infectious Diseases, 2018 Jun . 66(12), 1957-1959.
Externí odkaz:
https://www.jstor.org/stable/26526332
Autor:
Karol Krawiec, Aleksander Sławiński, Aleksander Ryczkowski, Małgorzata Neścior, Zuzanna Toruń, Anna Orzeł, Aleksandra Majchrzak, Piotr Piech
Publikováno v:
Journal of Education, Health and Sport, Vol 8, Iss 9, Pp 926-932 (2018)
The number of Clostridium difficile infections (CDI) has significantly increased in Poland and throughout Europe. Their treatment involves the administration of metronidazole, vancomycin or fidaxomicin as indicated in current recommendations. Despite
Externí odkaz:
https://doaj.org/article/44503265231a46fea8cd3be41c870834
Publikováno v:
Annals of Agricultural and Environmental Medicine. 28:535-540
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2023244a54b022269525e04ff5e1a26a
https://doi.org/10.26444/aaem/131121
https://doi.org/10.26444/aaem/131121
Autor:
Lynne V. McFarland
Publikováno v:
Antibiotics, Vol 4, Iss 2, Pp 160-178 (2015)
Clostridium difficile infections are a global clinical concern and are one of the leading causes of nosocomial outbreaks. Preventing these infections has benefited from multidisciplinary infection control strategies and new antibiotics, but the probl
Externí odkaz:
https://doaj.org/article/a1b56589d18b41c5a13ab677d8c0bc78
Publikováno v:
Science China Chemistry. 64:1736-1742
Tiacumicin B (also known as fidaxomicin or difimicin) is a marketed 18-membered macrolide antibiotic for the treatment of Clostridium difficile infections. Tiacumicin B is structurally characterized with two chlorine atoms substituted on the aromatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8302f3bf72b444f3b9583455d84ebf32
https://doi.org/10.1007/s11426-021-1072-6
https://doi.org/10.1007/s11426-021-1072-6
Publikováno v:
Revista Portuguesa de Farmacoterapia, Vol 5, Iss 4, Pp 16-25 (2013)
Objectives: Fidaxomicin is a macrocyclic antibiotic drug indicated for the treatment of Clostridium difficile infections (CDI). The purpose of this study was to evaluate from a societal perspective the cost-effectiveness and cost-utility of fidaxomic
Externí odkaz:
https://doaj.org/article/4f8f4a236a264d619a7bf63f9d9f415b
Publikováno v:
American Journal of Physical Medicine & Rehabilitation. 100:44-47
Objective Clostridium difficile infection is a common hospital-associated infection spread via patient contact or contaminated environments. The risk for spread of C difficile may be greater in inpatient rehabilitation units than in some hospital uni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::670cf6fd86d9db62f38425abde42166a
https://doi.org/10.1097/phm.0000000000001579
https://doi.org/10.1097/phm.0000000000001579
Publikováno v:
American Journal of Infection Control. 48:1019-1022
Objective To evaluate the effects of a best practice advisory (BPA) and a change in the Clostridioides (Clostridium) difficile testing algorithm on nosocomial C. difficile infection (CDI) rates. Methods This was a retrospective analysis at a tertiary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::003a9e96edfc4aab905296a200ad5136
https://doi.org/10.1016/j.ajic.2019.12.028
https://doi.org/10.1016/j.ajic.2019.12.028